Xcout Intel
H. Lundbeck B
H. Lundbeck is a global pharmaceutical company that focuses exclusively on researching, developing, and commercializing therapies for brain diseases such as neurology and psychiatry disorders. The company serves patients worldwide suffering from conditions like Alzheimer's disease, Parkinson's disease, migraine, depression, and schizophrenia.
Subscribe to see H. Lundbeck B’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
H. Lundbeck B at a glance
H. Lundbeck B is a health care company headquartered in Denmark. Xcout tracks 1 named person at H. Lundbeck B, including Charl van Zyl (President & CEO).
H. Lundbeck B leadership
- Charl van ZylPresident & CEO
H. Lundbeck B competitors
A few of H. Lundbeck B's closest competitors — see the full list of competitors and alternatives →
Novo Nordisk is a global healthcare company that researches, develops, and manufactures pharmaceutical products. The company provides medications and treatments for serious chronic diseases, including diabetes, obesity, and rare blood disorders like hemophilia, serving patients and healthcare professionals worldwide.
AlzeCure Pharma is a Swedish clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative diseases, particularly Alzheimer’s disease and related cognitive disorders. Its programs target disease mechanisms and symptoms, serving patients with serious central nervous system conditions through potential prescription medicines.
Gabather is a pharmaceutical company that develops therapeutics for neuropsychiatric disorders, focusing on treatments for conditions such as anxiety, depression, psychosis, pain, and Alzheimer’s disease. The company utilizes proprietary drug candidates targeting the GABAA receptor system to restore brain balance and enhance cognitive function.
Herantis Pharma Oyj is a clinical-stage biotechnology company that develops disease-modifying therapies to halt or reverse the progression of neurodegenerative diseases. The company focuses on researching and advancing innovative treatments, such as its lead drug candidate HER-096, to address significant unmet medical needs.
ALK-Abelló is a pharmaceutical and healthcare company that specializes in allergy research, diagnosis, and treatment. It provides products and solutions for respiratory allergies, anaphylaxis, food allergies, and asthma to patients and healthcare professionals.
Orion Oyj is a pharmaceutical and healthcare company that develops, manufactures, and markets medicines, active pharmaceutical ingredients, self-care products, and animal health products. The company serves patients, healthcare professionals, and animal owners by focusing on therapeutic areas such as oncology, respiratory diseases, neurology, women's health, and pain management.
Get H. Lundbeck B's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on H. Lundbeck B in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access